Latest News & Features
Americas
As IP professionals wait for agency cutbacks to be felt down the chain, the advice is to stay informed, manage budgets wisely, and use a mix of protections to weather any disruption, finds Marisa Woutersen. 13 March 2025
Americas
If law firms begin to fear the political repercussions of doing their jobs, the ‘whole system could unravel’. Muireann Bolger finds a concerned profession looking for leaders to oppose ‘open retribution’. 13 March 2025
Americas
John Squires’ IP monetisation history offers clues to his interests, but supporters say his focus on business and innovation signals a positive shift for the office. 13 March 2025
Big Pharma
The multinational claims Mylan Pharmaceuticals’ generic of its blockbuster weight loss drug infringes another new patent | Complaint similar but separate to previous lawsuit against Mylan and Sun Pharma. 11 March 2025
Americas
Appeals court affirms PTAB’s invalidation of three heart monitoring patents | Decision voids limited exclusion order that temporarily halted Apple watch imports into the US. 11 March 2025
Careers
The ex-Cadwell Clonts Reeder & Thomas trial attorney and litigator represents clients in all phases of litigation in both federal and state courts, bringing particular experience of disputes in the Eastern and Southern Districts of Texas. 11 March 2025
Americas
Return-to-office orders, redundancies, hiring freezes—do changes sweeping through the US agency ‘risk breaking the system’? Marisa Woutersen finds patent practitioners fearful of the future. 6 March 2025
Americas
Senior legal voices from the world’s biggest companies share perspective on International Women’s Day theme | Action is key as gender parity remains a distant goal–forecasted to take at least 134 years. 6 March 2025
Americas
New York biotech scores win as Fed Circ upholds preliminary injunction against Celltrion's biosimilar launch | Ruling follows intense scrutiny during Federal Circuit oral arguments | Decision follows similar rulings against Samsung Bioepis and Formycon. 6 March 2025
Big Pharma
Federal Circuit says only patents claiming the active ingredient of a drug are eligible for listing | Injunction against Teva temporarily paused in January pending the appeal court’s decision to review. 4 March 2025